MARKET

MCRB

MCRB

Seres Therapeutics Inc
NASDAQ
1.700
-0.280
-14.14%
Closed 19:55 11/09 EST
OPEN
1.940
PREV CLOSE
1.980
HIGH
2.050
LOW
1.680
VOLUME
184.23K
TURNOVER
0
52 WEEK HIGH
29.98
52 WEEK LOW
1.675
MARKET CAP
17.33M
P/E (TTM)
-0.3469
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MCRB last week (1102-1106)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Seres Therapeutics (MCRB) and Relay Therapeutics (RLAY)
TipRanks · 4d ago
Analysts Are Bullish on These Healthcare Stocks: Seres Therapeutics (MCRB), Nuvectis Pharma (NVCT)
TipRanks · 5d ago
Seres Therapeutics, Inc. Reports Third Quarter 2026 Financial Results and Outlines SER-155 Development Plans
NASDAQ · 5d ago
Seres Therapeutics Reports Q3 Results, Advances SER-155 Prevention Strategy
TipRanks · 5d ago
Seres Therapeutics GAAP EPS of -$1.63 misses by $0.63, revenue of $0.59M misses by $5.76M
Seeking Alpha · 5d ago
*Seres Therapeutics 3Q Loss $16.3M >MCRB
Dow Jones · 5d ago
*Seres Therapeutics 3Q Rev $593,000 >MCRB
Dow Jones · 5d ago
More
About MCRB
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

Webull offers Seres Therapeutics Inc stock information, including NASDAQ: MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.